GeneDx Holdings Corp. $WGS is Gagnon Securities LLC’s 2nd Largest Position

Gagnon Securities LLC decreased its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 5.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 253,534 shares of the company’s stock after selling 15,532 shares during the quarter. GeneDx comprises about 6.7% of Gagnon Securities LLC’s investment portfolio, making the stock its 2nd largest position. Gagnon Securities LLC owned about 0.88% of GeneDx worth $32,975,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Jones Financial Companies Lllp raised its stake in GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares in the last quarter. Ramirez Asset Management Inc. purchased a new stake in GeneDx during the fourth quarter valued at $33,000. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in GeneDx during the fourth quarter valued at $35,000. Quarry LP raised its stake in GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after purchasing an additional 209 shares in the last quarter. Finally, Empowered Funds LLC purchased a new stake in GeneDx during the fourth quarter valued at $73,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Trading Down 1.8%

NASDAQ WGS opened at $59.92 on Friday. The company’s 50-day moving average price is $54.95 and its 200-day moving average price is $90.19. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. The stock has a market cap of $1.78 billion, a PE ratio of -22.36 and a beta of 1.96. GeneDx Holdings Corp. has a 12 month low of $32.21 and a 12 month high of $170.87.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The company had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same quarter in the previous year, the company posted ($0.23) earnings per share. Equities research analysts forecast that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Insider Transactions at GeneDx

In related news, Director Casdin Capital, Llc purchased 185,000 shares of the business’s stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average cost of $42.60 per share, for a total transaction of $7,881,000.00. Following the completion of the acquisition, the director owned 3,367,164 shares in the company, valued at approximately $143,441,186.40. This trade represents a 5.81% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Keith A. Meister bought 533,758 shares of the stock in a transaction on Thursday, May 7th. The stock was purchased at an average price of $37.86 per share, with a total value of $20,208,077.88. Following the completion of the acquisition, the director directly owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. This trade represents a 16.53% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders bought 2,256,420 shares of company stock worth $93,144,340 and sold 77,287 shares worth $5,153,215. Corporate insiders own 29.60% of the company’s stock.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Hedge fund manager Eli Casdin is reportedly adding to his GeneDx position, which may be seen as a sign that some sophisticated investors still view the stock as undervalued. Hedge Funder Eli Casdin Is Loading up on GeneDx Shares
• Neutral Sentiment: Several law firms continue to remind investors about the pending securities class action and the August 3 lead-plaintiff deadline. These notices keep the lawsuit in focus, but do not add new operational developments. Investor Alert: Pomerantz Law Firm Reminds Investors…
• Neutral Sentiment: Additional legal updates from Rosen, Faruqi & Faruqi, Schall, Robbins, and others reinforce the litigation backdrop tied to GeneDx’s Fabric Genomics acquisition and the Q1 2026 selloff. ROSEN, TOP RANKED INVESTOR COUNSEL…
• Negative Sentiment: GeneDx CEO Katherine Stueland and CFO Kevin Feeley both sold shares this week. The company says the sales were for tax withholding tied to vesting equity awards, but insider selling can still weigh on sentiment. CEO Form 4 Filing
• Negative Sentiment: The biggest overhang remains the securities class action alleging GeneDx misled investors about reimbursement rates, margin pressure, and the impact of the Fabric Genomics acquisition after a major stock drop and write-off tied to the deal. GeneDx Holdings (WGS) Faces Securities Class Action…

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on WGS. Zacks Research downgraded shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 24th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $75.00 price target (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. BTIG Research dropped their price objective on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Jefferies Financial Group set a $150.00 price objective on shares of GeneDx in a research note on Monday, February 23rd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $130.00 price objective (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $96.43.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.